Cui 2013.

Study characteristics
Methods	Phase II parallel‐group RCT. Double‐blind study.
Participants	Untreated metastatic melanoma harbouring no mutations in KRAS, NRAS, BRAF, or c‐kit genes. Participants randomised: 114.
Interventions	Two‐arm trial: Dacarbazine 250 mg/m² IV daily on days 1 to 5 and endostar 7.5 mg/m² IV daily on days 1 to 14 every 3 weeks up to 12 cycles (N = 57); Dacarbazine 250 mg/m² IV daily on days 1 to 5 (N = 57).
Outcomes	Overall survival. Progression‐free survival. Tumour response. Toxicity.
Notes	Cross‐over: not reported. Quality of life: not reported. Participants with brain metastasis: excluded. Median follow‐up: not available.
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Quote: "Simple stratified randomization with permuted blocks of size 2 was used to create a prospective randomization schedule". Comment: Randomisation method was adequate.
Allocation concealment (selection bias)	Low risk	Quote: "Random assignment of patients was performed by designated personnel at each participating site in a double‐blind fashion such that the investigator and patient did not know the treatment assignment" Comment: Allocation was likely concealed.
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Quote: "Double‐blind". Comment: This method ensured low risk of performance bias.
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Quote: "Double‐blind". Comment: This method ensured low risk of detection bias.
Incomplete outcome data (attrition bias) All outcomes	Low risk	Missing outcome data were balanced across intervention groups, with similar reasons for missing data across groups.
Selective reporting (reporting bias)	Low risk	No differences between protocol and published report.
Other bias	Low risk	The study appeared to be free of other sources of bias.